Targeted therapies in myeloid leukemias
Related Experiment Video
Updated: Aug 17, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
1Harvard Medical School, Brigham & Women's Hospital, Harvard Institute of Medicine, Boston, USA.
Abstract:
There is still a compelling need to improve therapeutic outcome in AML. However, during the past several years our understanding of the genetic basis of AML, and the nature of the mutations that contribute to the phenotype, have been elucidated in cell culture and murine models of leukemia. The validation of various mutant leukemogenic gene products has in turn led to the development of an expanding group of molecular targeted therapies that have potential to improve the therapeutic window for treatment of AML.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Differentiation of Common Myeloid Progenitor Cells
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

